Jonathan M Hernandez
Overview
Explore the profile of Jonathan M Hernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pu T, Gustafson A, Luberice K, Akmal S, Li W, Hernandez J, et al.
Ann Surg
. 2024 Aug;
PMID: 39145378
Objective: To investigate if underrepresentation of racial and ethnic minorities exists in metastatic colorectal carcinoma (CRC) clinical trials. Summary Background Data: Representation of vulnerable subpopulations is essential for generalizability of...
12.
Dominguez D, Eade A, Aversa J, Hagerty B, Blakely A, Davis J, et al.
Heliyon
. 2024 Aug;
10(15):e34714.
PMID: 39144996
Background: Extrahepatic biliary neuroendocrine tumors (EBNETs) are rare. We aimed to characterize EBNETs including factors associated with survival. Methods: The National Cancer Database was queried for patients with EBNETs from...
13.
Eade A, Friedman L, Larrain C, Rainey A, Hernandez J, Chawla A, et al.
Ann Surg Oncol
. 2024 Jul;
31(10):6373-6374.
PMID: 39048905
No abstract available.
14.
Webster B, Ricketts C, Vocke C, Gamble D, Crooks D, Yang Y, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2400188.
PMID: 39038244
Comprehensive molecular characterization and effective therapy in a rare case of metastatic renal oncocytoma.
15.
Victory J, Smith E, Ryan C, Lambdin J, Sarvestani A, Friedman L, et al.
J Gastrointest Oncol
. 2024 Jul;
15(3):1348-1354.
PMID: 38989414
Background: Treatment of advanced liver tumors remains challenging. Although immune checkpoint inhibition has revolutionized treatment for many cancers, responses in colorectal liver metastases and biliary tract cancers remain suboptimal. Investigation...
16.
Bojmar L, Zambirinis C, Hernandez J, Chakraborty J, Shaashua L, Kim J, et al.
Nat Med
. 2024 Jun;
30(8):2170-2180.
PMID: 38942992
Metastasis occurs frequently after resection of pancreatic cancer (PaC). In this study, we hypothesized that multi-parametric analysis of pre-metastatic liver biopsies would classify patients according to their metastatic risk, timing...
17.
McClelland P, Gregory S, Nah S, Hernandez J, Davis J, Blakely A
Ann Surg Oncol
. 2024 Jun;
31(9):6237-6251.
PMID: 38874874
Background: Mucinous adenocarcinoma of the appendix (MACA) follows a complex disease course with variable survival. Large-scale predictive modeling may determine subtle yet important prognostic factors otherwise unseen in smaller cohort...
18.
Arakawa Y, Jo U, Kumar S, Sun N, Elloumi F, Thomas A, et al.
Cancer Res Commun
. 2024 Mar;
4(3):834-848.
PMID: 38451783
Significance: ACC is a rare endocrine cancer with poor prognosis and limited therapeutic options. We report that TAK-243 is active alone and in combination with currently used therapies and with...
19.
Radtke A, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, et al.
Cancer Cell
. 2024 Mar;
42(3):444-463.e10.
PMID: 38428410
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic...
20.
Revsine M, Wang L, Forgues M, Behrens S, Craig A, Liu M, et al.
Cell Rep Med
. 2024 Jan;
5(2):101394.
PMID: 38280378
A tumor ecosystem constantly evolves over time in the face of immune predation or therapeutic intervention, resulting in treatment failure and tumor progression. Here, we present a single-cell transcriptome-based strategy...